Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 4/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | FADS1 | O60427 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28686131 | 0.84 | NTRK1 (0.46) | NTRK1NTRK3NTRK2GRM4 | |
| SCHEMBL28686124 | 0.81 | NTRK1 (0.59) | NTRK1NTRK3NTRK2GRM4LRRK2 | |
| SCHEMBL28700912 | 0.81 | NTRK1 (0.59) | NTRK1NTRK3NTRK2GRM4GRM5 | |
| SCHEMBL28697267 | 0.81 | NTRK1 (0.64) | NTRK1NTRK3NTRK2 | |
| SCHEMBL28686122 | 0.79 | NTRK1 (0.60) | NTRK1NTRK3NTRK2GRM4LRRK2 | |
| SCHEMBL28684850 | 0.79 | NTRK1 (0.38) | NTRK1NTRK3NTRK2GRM5 | |
| SCHEMBL28698672 | 0.77 | NTRK1 (0.53) | NTRK1NTRK3NTRK2GRM5 | |
| SCHEMBL12269783 | 0.76 | LRRK2 (0.49) | LRRK2GRM5 | |
| SCHEMBL28690954 | 0.76 | NTRK1 (0.54) | NTRK1NTRK3NTRK2 | |
| SCHEMBL29390713 | 0.75 | NTRK1 (0.50) | NTRK1NTRK3NTRK2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114072387-B | Indazole compound, pharmaceutical composition and application thereof | 暨南大学 | 2024-03-08 | — | — | CN | disclosed |
| EP-4056558-A1 | INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | Jinan University (CN) | 2022-09-14 | — | — | EP | disclosed |
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | JINAN UNIVERSITY (CN) | 2022-09-08 | — | — | US | disclosed |
| CN-114072387-A | Indazole compound and medicinal composition and application thereof | 暨南大学 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281821-A1 | INDAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS | TNK2, TNNI3K, CSNK1G3 | NTRK1 63/4885NTRK3 42/4885NTRK2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.